Australia’s Therapeutic Goods Administration (TGA) is advancing its Unique Device Identification system (AusUDID), bringing the country further into alignment with global UDI standards. With phased implementation beginning in the coming years, medical device manufacturers must prepare for new data submission, labeling, and ongoing compliance requirements.
Australia’s approach reflects global harmonization efforts, aligning with established UDI frameworks such as the FDA and elements of EUDAMED. For manufacturers operating internationally, this creates both opportunity and complexity — requiring coordinated data management across multiple regulatory systems.
LexisNexis Life Sciences simplifies that complexity. We support manufacturers across the entire product lifecycle — from initial market entry and UDI data preparation to ongoing updates, change management, and post-market compliance. Our global regulatory expertise and technology-driven solutions help ensure your device data stays accurate, synchronized, and inspection-ready, so you can focus on innovation while we help safeguard compliance.
Gain exclusive insights from Australia’s leading regulatory device summit. Discover how expectations are shifting, where submissions face delays, and what quality evidence regulators prioritize. Learn what your team should focus on to stay ahead in a changing landscape.
Australia’s Therapeutic Goods Administration (TGA) is rolling out a phased regulatory compliance framework. Higher-risk devices are prioritized first, with requirements expanding to lower-risk categories over time.
Understanding UDI obligations across global health authorities can be complex. Whether you are preparing for initial submission, managing product data updates, or aligning compliance across multiple markets, our regulatory experts provide practical guidance tailored to your organization’s needs.
